Answers are grounded in this paper and cite their sources.
In this trial comparing the combined tofacitinib doses with a TNF inhibitor in a cardiovascular risk-enriched population, risks of MACE and cancers were higher with tofacitinib and did not meet noninferiority criteria. Several adverse events were more common with tofacitinib. (Funded by Pfizer; ORAL Surveillance ClinicalTrials.gov number, NCT02092467.).
No takes yet. Share an insight, caveat, or question.
Ytterberg et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: